Avadel Pharmaceuticals Statistics
Share Statistics
Avadel Pharmaceuticals has 96.74M
shares outstanding. The number of shares has increased by 0.53%
in one year.
| Shares Outstanding | 96.74M |
| Shares Change (YoY) | 0.53% |
| Shares Change (QoQ) | 0.28% |
| Owned by Institutions (%) | 82.38% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 307 |
| FTD / Avg. Volume | 0.03% |
Short Selling Information
The latest short interest is 10.18M, so 10.52% of the outstanding
shares have been sold short.
| Short Interest | 10.18M |
| Short % of Shares Out | 10.52% |
| Short % of Float | 12.37% |
| Short Ratio (days to cover) | 11.42 |
Valuation Ratios
The PE ratio is -20.48 and the forward
PE ratio is 13.65.
Avadel Pharmaceuticals's PEG ratio is
0.27.
| PE Ratio | -20.48 |
| Forward PE | 13.65 |
| PS Ratio | 5.91 |
| Forward PS | 1.8 |
| PB Ratio | 13.54 |
| P/FCF Ratio | -21.32 |
| PEG Ratio | 0.27 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for Avadel Pharmaceuticals.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.75,
with a Debt / Equity ratio of 0.02.
| Current Ratio | 2.75 |
| Quick Ratio | 2.33 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | -0.05 |
| Debt / FCF | -0.04 |
| Interest Coverage | -3.91 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $899,558.51 |
| Profits Per Employee | $-259,744.68 |
| Employee Count | 188 |
| Asset Turnover | 1.03 |
| Inventory Turnover | 0.75 |
Taxes
| Income Tax | -247K |
| Effective Tax Rate | 0.5% |
Stock Price Statistics
The stock price has increased by -41.9% in the
last 52 weeks. The beta is 1.4, so Avadel Pharmaceuticals's
price volatility has been higher than the market average.
| Beta | 1.4 |
| 52-Week Price Change | -41.9% |
| 50-Day Moving Average | 8.26 |
| 200-Day Moving Average | 10.97 |
| Relative Strength Index (RSI) | 55.06 |
| Average Volume (20 Days) | 1,211,433 |
Income Statement
In the last 12 months, Avadel Pharmaceuticals had revenue of 169.12M
and earned -48.83M
in profits. Earnings per share was -0.51.
| Revenue | 169.12M |
| Gross Profit | 153.84M |
| Operating Income | -42.4M |
| Net Income | -48.83M |
| EBITDA | -35.57M |
| EBIT | -38.25M |
| Earnings Per Share (EPS) | -0.51 |
Full Income StatementBalance Sheet
The company has 51.37M in cash and 1.7M in
debt, giving a net cash position of 49.67M.
| Cash & Cash Equivalents | 51.37M |
| Total Debt | 1.7M |
| Net Cash | 49.67M |
| Retained Earnings | -794.33M |
| Total Assets | 167.95M |
| Working Capital | 88.33M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -46.91M
and capital expenditures 0, giving a free cash flow of -46.91M.
| Operating Cash Flow | -46.91M |
| Capital Expenditures | n/a |
| Free Cash Flow | -46.91M |
| FCF Per Share | -0.49 |
Full Cash Flow StatementMargins
Gross margin is 90.97%, with operating and profit margins of -25.07% and -28.87%.
| Gross Margin | 90.97% |
| Operating Margin | -25.07% |
| Pretax Margin | -29.02% |
| Profit Margin | -28.87% |
| EBITDA Margin | -21.03% |
| EBIT Margin | -25.07% |
| FCF Margin | -27.74% |
